The KRAS G12C mutation disrupts the normal balance between GDP and GTP binding, reduces the binding of KRAS to GTPase-activating proteins (GAPs), and leads to an overactivation of KRAS in its GTP-bound state, ultimately promoting tumor initiation and growth. The gene discussed is KRAS; the disease is neoplasm.